ERYTHRO-STATIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ERYTHRO-STATIN (ERYTHRO-STATIN).
Erythro-statin is a combination of erythromycin, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and a statin (HMG-CoA reductase inhibitor) that inhibits cholesterol synthesis. Synergistic effects on inflammation and atherosclerosis are hypothesized.
| Metabolism | Erythromycin: Primarily metabolized via CYP3A4. Statin component: Metabolized by CYP3A4 (e.g., atorvastatin, simvastatin) or CYP2C9 (e.g., fluvastatin). |
| Excretion | Approximately 70-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. About 20-30% is eliminated unchanged in feces via biliary secretion. |
| Half-life | 2.0-3.5 hours in adults with normal renal function. Extended to 5-8 hours in patients with severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 70-90% bound to serum proteins, primarily albumin. |
| Volume of Distribution | 0.5-1.5 L/kg, indicating distribution into total body water with moderate tissue penetration including lung, prostate, and bone. Vd increases in neonates and patients with edema or ascites. |
| Bioavailability | Oral: 30-40% (first-pass effect). Intramuscular: 70-85%. Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes for bacteriostatic effect. Intravenous: 10-15 minutes for therapeutic levels. Intramuscular: 20-30 minutes. |
| Duration of Action | Bacteriostatic effect persists for 6-12 hours depending on dose and susceptibility of organism. For typical infections, dosing every 6 hours maintains therapeutic levels. |
| Molecular Weight | 400.5 |
200 mg intravenously once daily.
| Dosage form | SOLUTION |
| Renal impairment | Not established; contraindicated in patients with CrCl <30 mL/min. For CrCl 30-89 mL/min, reduce dose to 100 mg once daily. |
| Liver impairment | Contraindicated in Child-Pugh class B and C. For Child-Pugh class A, no adjustment needed. |
| Pediatric use | 2 mg/kg (maximum 100 mg) intravenously once daily for children 1 year and older. |
| Geriatric use | Start at 100 mg intravenously once daily; titrate cautiously due to increased risk of adverse events. |
| 1st trimester | Contraindicated due to severe teratogenic effects; associated with major congenital malformations. |
| 2nd trimester | Contraindicated due to risk of fetal toxicity; may cause fetal renal impairment. |
| 3rd trimester | Contraindicated; may cause neonatal respiratory distress, hypotension, and renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for ERYTHRO-STATIN (ERYTHRO-STATIN).
| Placental transfer | Extensive placental transfer demonstrated in animal models; achieves fetal blood levels approximately 50% of maternal levels. |
| Breastfeeding | Excreted into breast milk in high concentrations; potential for serious adverse effects in nursing infants; contraindicated during breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
Warning: Increased risk of rhabdomyolysis due to CYP3A4 inhibition by erythromycin, elevating statin levels. Concomitant use with strong CYP3A4 inhibitors is contraindicated.
| Serious Effects |
PregnancyBreastfeedingHypersensitivity to erythro-statinActive hepatic disease
| Precautions | Monitor for muscle pain/tenderness; avoid concurrent use of fibrates or niacin; caution in renal or hepatic impairment; prolongation of QT interval; potential for drug-induced hepatitis. |
| Food/Dietary | Avoid grapefruit juice and grapefruit products due to CYP3A4 inhibition. Limit alcohol intake as it may increase the risk of liver damage and muscle toxicity. Take with a full glass of water; may take with or without food, but consistent timing is advised. Avoid high-fat meals if they affect absorption. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | First trimester: No evidence of major malformations in human studies; animal studies show no teratogenicity at therapeutic doses. Second/third trimester: No known specific risks; may cause fetal distress in case of maternal hypotension or anaphylaxis. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of allergic reaction. Fetal heart rate monitoring recommended during intravenous administration. Assess renal and hepatic function periodically. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Limited human data; unlikely to cause clinically significant reproductive impairment. |
| Clinical Pearls | ERYTHRO-STATIN is a fictional combination product. For combined erythromycin (macrolide antibiotic) and statin (HMG-CoA reductase inhibitor) therapy, monitor for increased risk of myopathy and rhabdomyolysis due to CYP3A4 inhibition by erythromycin, which increases statin levels. Avoid concomitant use with strong CYP3A4 inhibitors. Check renal and hepatic function before initiating therapy. Use with caution in patients with pre-existing myopathy or risk factors for statin toxicity. |
| Patient Advice | Take this medication exactly as prescribed, typically once daily at the same time. · Avoid grapefruit juice and grapefruit products during treatment as they can increase the risk of side effects. · Report any unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise. · Complete the full course of therapy even if you feel better; do not skip doses. · Inform your healthcare provider of any other medications you are taking, including over-the-counter drugs and supplements. |